The stock price of Biogen Inc (NASDAQ: BIIB) has surged by 0.64 when compared to previous closing price of 126.56, but the company has seen a -4.27% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-18 that Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to
Is It Worth Investing in Biogen Inc (NASDAQ: BIIB) Right Now?
Biogen Inc (NASDAQ: BIIB) has a price-to-earnings ratio that is above its average at 12.58x. The stock has a 36-month beta value of 0.15. Opinions on the stock are mixed, with 13 analysts rating it as a “buy,” 5 as “overweight,” 19 as “hold,” and 0 as “sell.”
The public float for BIIB is 146.28M, and at present, short sellers hold a 2.59% of that float. On June 18, 2025, the average trading volume of BIIB was 1.67M shares.
BIIB’s Market Performance
BIIB stock saw a decrease of -4.27% in the past week, with a monthly decline of -1.60% and a quarterly a decrease of -9.94%. The volatility ratio for the week is 1.62%, and the volatility levels for the last 30 days are 1.79% for Biogen Inc (BIIB). The simple moving average for the last 20 days is -2.26% for BIIB stock, with a simple moving average of -16.15% for the last 200 days.
Analysts’ Opinion of BIIB
Many brokerage firms have already submitted their reports for BIIB stocks, with HSBC Securities repeating the rating for BIIB by listing it as a “Hold.” The predicted price for BIIB in the upcoming period, according to HSBC Securities is $118 based on the research report published on April 28, 2025 of the current year 2025.
Bernstein gave a rating of “Mkt Perform” to BIIB, setting the target price at $160 in the report published on February 11th of the current year.
BIIB Trading at 2.62% from the 50-Day Moving Average
After a stumble in the market that brought BIIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.48% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIIB starting from Singhal Priya, who sale 3,806 shares at the price of $126.25 back on May 19 ’25. After this action, Singhal Priya now owns 5,427 shares of Biogen Inc, valued at $480,508 using the latest closing price.
Singhal Priya, the Officer of Biogen Inc, proposed sale 3,806 shares at $126.25 during a trade that took place back on May 19 ’25, which means that Singhal Priya is holding shares at $480,508 based on the most recent closing price.
Stock Fundamentals for BIIB
Current profitability levels for the company are sitting at:
- 0.23 for the present operating margin
- 0.76 for the gross margin
The net margin for Biogen Inc stands at 0.15. The total capital return value is set at 0.1. Equity return is now at value 9.19, with 5.42 for asset returns.
Based on Biogen Inc (BIIB), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at 0.39. The debt to equity ratio resting at 0.39. The interest coverage ratio of the stock is 9.43.
Currently, EBITDA for the company is 2.83 billion with net debt to EBITDA at 1.49. When we switch over and look at the enterprise to sales, we see a ratio of 2.31. The receivables turnover for the company is 4.92for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.44.
Conclusion
To sum up, Biogen Inc (BIIB) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
